Literature DB >> 12684829

Diagnosis and management of carcinoma of unknown primary in the head and neck.

Wolfgang J Issing1, Behsad Taleban, Stefan Tauber.   

Abstract

Carcinoma of unknown primary is defined as the histological diagnosis of metastasis without the detection of a primary tumor. In the literature, the incidence of CUP in all patients with a malignant disease is said to be between 3% and 15%. The most frequent histopathological results of CUP metastases are adenocarcinoma, followed by undifferentiated carcinoma and squamous cell carcinoma. In this retrospective investigation the clinical records of 167 patients were studied. All patients had been admitted and treated for cervical CUP at the Department of Otorhinolaryngology of the Grosshadern Clinic from 1979 to 1998. Cervical swelling was the first noted symptom in all cases, followed by pain and dysphagia. The study group comprised 134 men and 33 women with an average age of 55 years at admission. Squamous cell carcinoma (n=123) was the predominant histopathological finding of the cervical lymph nodes. During the 10-year follow-up, a primary tumor was detected in 36 (21.5%) of the 167 initially diagnosed CUP patients. In over 90% of these cases the tumor was localized in the head and neck region. The most frequent origin of the tumor was the tonsilla palatina (n=7). Neck dissection and additional postoperative radiotherapy was performed in 118 (70.7%) of the 167 CUP patients. Primary radiotherapy was the treatment of choice in 28 patients; eight patients received combined radio-chemotherapy as the primary treatment and seven patients were treated with chemotherapy alone. Six patients had no treatment. Comparison of different treatment protocols revealed a significant difference in patient survival: in comparison with primary radiotherapy alone or neck dissection and postoperative radiotherapy, the survival rate improved significantly in patients that received a bilateral tonsillectomy in addition to neck dissection and postoperative radiotherapy. The treatment of choice in patients with cervical CUP should be a surgical procedure including (radical) neck dissection and diagnostic bilateral tonsillectomy followed by postoperative radiation of the cervical lymph drainage. Bilateral tonsillectomy is especially important and is correlated with a significant improvement of the survival rate in CUP patients. Additional postoperative radiation of the entire pharyngeal and laryngeal mucosa should also be considered in order to treat a possible small primary tumor in this region.

Entities:  

Mesh:

Year:  2003        PMID: 12684829     DOI: 10.1007/s00405-003-0585-z

Source DB:  PubMed          Journal:  Eur Arch Otorhinolaryngol        ISSN: 0937-4477            Impact factor:   2.503


  29 in total

1.  The case for branchiogenic cancer (malignant branchioma).

Authors:  H MARTIN; H M MORFIT; H EHRLICH
Journal:  Ann Surg       Date:  1950-11       Impact factor: 12.969

2.  [Cervical lymphatic metastases in an unknown primary tumor: starting point, therapy, prognosis].

Authors:  H Habermalz; E Gerstenberg; A Kuckuck; H Ernst
Journal:  Strahlentherapie       Date:  1972-09

3.  Unknown primary squamous cell carcinoma metastatic to the neck.

Authors:  R C Wang; H Goepfert; A E Barber; P Wolf
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1990-12

4.  Metastatic carcinoma in cervical nodes with an unknown primary lesion.

Authors:  R H Jesse; L E Neff
Journal:  Am J Surg       Date:  1966-10       Impact factor: 2.565

Review 5.  Cervical lymph node metastases from occult squamous cell carcinoma: cut down a tree to get an apple?

Authors:  C Nieder; V Gregoire; K K Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-07-01       Impact factor: 7.038

Review 6.  Early metastatic cancer of unknown primary origin at presentation. A clinical study of 302 consecutive autopsied patients.

Authors:  T Le Chevalier; E Cvitkovic; P Caille; J Harvey; G Contesso; M Spielmann; J Rouesse
Journal:  Arch Intern Med       Date:  1988-09

7.  2[F]-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation.

Authors:  M Jungehülsing; K Scheidhauer; M Damm; U Pietrzyk; H Eckel; H Schicha; E Stennert
Journal:  Otolaryngol Head Neck Surg       Date:  2000-09       Impact factor: 3.497

8.  Cervical metastasis from the unknown primary tumor.

Authors:  A L Oen; M F de Boer; W C Hop; P Knegt
Journal:  Eur Arch Otorhinolaryngol       Date:  1995       Impact factor: 2.503

9.  [Lymphatic node-metastasis of the neck in unknown primary tumour (author's transl)].

Authors:  J Knothe; F Fritsche
Journal:  Laryngol Rhinol Otol (Stuttg)       Date:  1980-04

10.  Diagnostic strategies in cervical carcinoma of an unknown primary (CUP).

Authors:  Inge Haas; Thomas K Hoffmann; Rainer Engers; Uwe Ganzer
Journal:  Eur Arch Otorhinolaryngol       Date:  2002-05-01       Impact factor: 2.503

View more
  17 in total

1.  Combined p16 and p53 expression in cervical cancer of unknown primary and other prognostic parameters : A single-center analysis.

Authors:  Müjdat Yildirim; Jens Müller von der Grün; Ria Winkelmann; Emmanouil Fokas; Franz Rödel; Hanns Ackermann; Claus Rödel; Panagiotis Balermpas
Journal:  Strahlenther Onkol       Date:  2017-01-31       Impact factor: 3.621

2.  Prognostic and diagnostic accuracy of [18F]FDG-PET/CT in 190 patients with carcinoma of unknown primary.

Authors:  Pavel Fencl; Otakar Belohlavek; Magdalena Skopalova; Monika Jaruskova; Iva Kantorova; Katerina Simonova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-01       Impact factor: 9.236

3.  Cancer of unknown primary (CUP) of the head and neck: retrospective analysis of 81 patients.

Authors:  Basel Al Kadah; Giorgos Papaspyrou; Maximilian Linxweiler; Bernhard Schick; Christian Rübe; Benjamin Simeon Büchler; Marcus Niewald
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-03-17       Impact factor: 2.503

4.  p16 status, pathologic and clinical characteristics, biomolecular signature, and long-term outcomes in head and neck squamous cell carcinomas of unknown primary.

Authors:  Lanea M Keller; Thomas J Galloway; Thomas Holdbrook; Karen Ruth; Donghua Yang; Cara Dubyk; Douglas Flieder; Miriam N Lango; Ranee Mehra; Barbara Burtness; John A Ridge
Journal:  Head Neck       Date:  2014-01-13       Impact factor: 3.147

Review 5.  Diagnosis and management of neck metastases from an unknown primary.

Authors:  L Calabrese; B A Jereczek-Fossa; J Jassem; A Rocca; R Bruschini; R Orecchia; F Chiesa
Journal:  Acta Otorhinolaryngol Ital       Date:  2005-02       Impact factor: 2.124

6.  Management of lymph node metastases from an unknown primary site to the head and neck (Review).

Authors:  Shi Min Zhuang; Xi-Fu Wu; Jing-Jia Li; Ge-Hua Zhang
Journal:  Mol Clin Oncol       Date:  2014-07-29

Review 7.  Unknown primary cancer of the head and neck: a multidisciplinary approach.

Authors:  Laura Cerezo; Eduardo Raboso; Ana Isabel Ballesteros
Journal:  Clin Transl Oncol       Date:  2011-02       Impact factor: 3.405

8.  Therapeutic efficacy of selective intra-arterial chemoradiotherapy with docetaxel and nedaplatin for fixed bulky nodal disease in head and neck cancer of unknown primary.

Authors:  Joichi Heianna; Wataru Makino; Hitoshi Hirakawa; Shinya Agena; Hayato Tomita; Takuro Ariga; Kazuki Ishikawa; Shota Takehara; Hitoshi Maemoto; Sadayuki Murayama
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-10-10       Impact factor: 2.503

9.  Occult Primary Head and Neck Squamous Cell Carcinoma: Utility of Discovering Primary Lesions.

Authors:  Kara S Davis; J Kenneth Byrd; Vikas Mehta; Simon I Chiosea; Seungwon Kim; Robert L Ferris; Jonas T Johnson; Umamaheswar Duvvuri
Journal:  Otolaryngol Head Neck Surg       Date:  2014-05-08       Impact factor: 3.497

Review 10.  Role of (18)F-FDG PET/CT in pre and post treatment evaluation in head and neck carcinoma.

Authors:  Bundhit Tantiwongkosi; Fang Yu; Anand Kanard; Frank R Miller
Journal:  World J Radiol       Date:  2014-05-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.